Contineum Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2023 to 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Contineum Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2023 to 2024.
  • Contineum Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$17M, a 76.2% decline year-over-year.
  • Contineum Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$50.9M, a 417% decline year-over-year.
  • Contineum Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$50.9M, a 417% decline from 2023.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$50.9M -$67M -417% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-06
2023 $16.1M Jan 1, 2023 Dec 31, 2023 10-K 2025-03-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.